An observational study in Parkinsons, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Washington University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Parkinson Disease by Washington University School of Medicine — 7 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Washington University School of Medicine.
Among the 32 studies in Parkinson Disease by Washington University School of Medicine, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2016, is one of 13 observational ones, and was the 11th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →7 of the 32 studies in Parkinson Disease by Washington University School of Medicine are open now, in 2 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 50+
Washington University School of Medicine · Sites in United States
Ages 40+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Washington University School of Medicine · Sites in United States
Ages 50+ · Healthy volunteers
Washington University School of Medicine · Sites in United States, Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1
First in 2004; this study’s year is marked. 1 started in 2016.
This study's planned enrollment of 320 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 31 across the 19 interventional studies, 174 across the 13 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
1 of the studies in Parkinson Disease by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05826457Washington University School of MedicineNorth American Prodromal Synucleinopathy Consortium Stage 2 | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Parkinson Disease by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.
The purpose of this study is to use a brain imaging method called PIB PET and VAT PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia. The investigators will be including both PD and normal subjects in this study. This a long term study and we are considering including a total of 320 participants in this protocol.
Participants with and without Parkinson disease will be recruited from the Movement Disorders Center at Washington University, the St. Louis metro area, and throughout the midwest region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with Parkinsons Disease
Radiation: PiB and VAT
Individuals without Parkinsons Disease
Radiation: PiB and VAT
There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
Investigations of Dementia in Parkinsons Disease
The investigators will perform memory/thinking testing, Lumbar puncture (LP), Magnetic Resonance Imaging (MRI) and (PET) scans to help to determine the cause(s) of memory and thinking in Parkinson Disease. The memory and thinking testing by phone on average at 1.5 years through study completion and then in person on average at 3 years through study completion, this will help monitor if there is any decline in memory and thinking. The Lumbar Puncture is done on willing participants on average at 3 years through study completion to assess for any abnormal proteins and correlate these with any changes in memory and thinking. The MRI is done on average at 3 years through study completion for any abnormal signs or changes in regards to dementia at 3 years. The (PiB) \& (VAT) PET scans will be performed on average at 3 years through study completion, which will be analyzed to assess for changes in regards to abnormal proteins and signs of dementia.
Time frame: 2030
Plan to share: Yes — de-identified data that has been published will be shared upon request.
Supporting information: Informed consent form
Time frame: after publication of the results
Access criteria: request from a legitimate investigator with a proposal sent to and approved by Joel S Perlmutter at Washington University.
No publications or documents are linked to this record.
The record gives a start of Jun 2016, a primary completion of Mar 2030 and a completion of Mar 2030. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →